For using their combined expertise in virology and in multisubunit protein production to engineer virus-like particles (VLPs), which will allow for rapid testing of the neutralization capacity of recovered patient sera (in collaboration with the Blish lab) or designed antibodies targeting the S protein (in collaboration with the Wells lab).
- Funded by Emergent Ventures Fast Grants
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19start year
-99Known Financial Commitments (USD)
$0Funder
Emergent Ventures Fast GrantsPrincipal Investigator
Dr. Judith FrydmanResearch Location
United States of AmericaLead Research Institution
Stanford UniversityResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
For using their combined expertise in virology and in multisubunit protein production to engineer virus-like particles (VLPs), which will allow for rapid testing of the neutralization capacity of recovered patient sera (in collaboration with the Blish lab) or designed antibodies targeting the S protein (in collaboration with the Wells lab).